- Home
- BFRI vs SLXN Comparison
BFRI vs SLXN Comparison
Compare BFRI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- SLXN
- Stock Information
- Founded
- BFRI 1997
- SLXN 2008
- Country
- BFRI United States
- SLXN Israel
- Employees
- BFRI N/A
- SLXN N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- BFRI Health Care
- SLXN
- Exchange
- BFRI Nasdaq
- SLXN NYSE
- Market Cap
- BFRI 7.5M
- SLXN 7.3M
- IPO Year
- BFRI 2021
- SLXN N/A
- Fundamental
- Price
- BFRI $0.88
- SLXN $0.80
- Analyst Decision
- BFRI Strong Buy
- SLXN Strong Buy
- Analyst Count
- BFRI 1
- SLXN 1
- Target Price
- BFRI $2.75
- SLXN $5.00
- AVG Volume (30 Days)
- BFRI 238.6K
- SLXN 707.7K
- Earning Date
- BFRI 08-13-2025
- SLXN 08-21-2025
- Dividend Yield
- BFRI N/A
- SLXN N/A
- EPS Growth
- BFRI N/A
- SLXN N/A
- EPS
- BFRI N/A
- SLXN N/A
- Revenue
- BFRI $37,997,000.00
- SLXN N/A
- Revenue This Year
- BFRI $11.75
- SLXN N/A
- Revenue Next Year
- BFRI $17.09
- SLXN N/A
- P/E Ratio
- BFRI N/A
- SLXN N/A
- Revenue Growth
- BFRI 14.28
- SLXN N/A
- 52 Week Low
- BFRI $0.54
- SLXN $0.58
- 52 Week High
- BFRI $2.22
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- BFRI 72.09
- SLXN N/A
- Support Level
- BFRI $0.66
- SLXN N/A
- Resistance Level
- BFRI $0.91
- SLXN N/A
- Average True Range (ATR)
- BFRI 0.07
- SLXN 0.00
- MACD
- BFRI 0.02
- SLXN 0.00
- Stochastic Oscillator
- BFRI 80.56
- SLXN 0.00
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.